二甲双胍治疗对乳腺癌发病率及预后的影响

Q4 Medicine

Archive of Oncology Pub Date : 2012-01-01 DOI:10.2298/AOO1204062P

Ðordje Popovic, L. Popović, E. Stokic, D. Tomić-Naglić, M. Mitrović, B. Kovačev-Zavišić

{"title":"二甲双胍治疗对乳腺癌发病率及预后的影响","authors":"Ðordje Popovic, L. Popović, E. Stokic, D. Tomić-Naglić, M. Mitrović, B. Kovačev-Zavišić","doi":"10.2298/AOO1204062P","DOIUrl":null,"url":null,"abstract":"Diabetes mellitus type 2 and malignant diseases are among the most frequent causes of morbidity and mortality worldwide. Number of studies showed that breast carcinoma and other cancers are more frequent and have worse prognosis in patients with diabetes. The mechanisms of effect of type 2 diabetes to frequency and prognosis of breast carcinoma are complex and besides a direct effect of insulin resistance, hyperinsulinemia and hyperglycemia, they include the effect of accompanying obesity and anti-diabetic therapy. One of the anti-diabetic drugs that reduces frequency and improves prognosis of breast carcinoma is metformin. Anticancer effects of metformin are indirect (insulin dependent) and direct (insulin independent). Insulin-dependent and insulin-independent antitumor effect of metformin opens the door for implementation of this drug in therapy and prevention of breast cancer and other malignant diseases even in patients without type 2 diabetes. This paper presents literature data on mechanisms of type 2 diabetes impact to the risk of development and prognosis of breast cancer and the anticancer potential of metformin.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2298/AOO1204062P","citationCount":"3","resultStr":"{\"title\":\"Influence of metformin therapy on breast cancer incidence and prognosis\",\"authors\":\"Ðordje Popovic, L. Popović, E. Stokic, D. Tomić-Naglić, M. Mitrović, B. Kovačev-Zavišić\",\"doi\":\"10.2298/AOO1204062P\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Diabetes mellitus type 2 and malignant diseases are among the most frequent causes of morbidity and mortality worldwide. Number of studies showed that breast carcinoma and other cancers are more frequent and have worse prognosis in patients with diabetes. The mechanisms of effect of type 2 diabetes to frequency and prognosis of breast carcinoma are complex and besides a direct effect of insulin resistance, hyperinsulinemia and hyperglycemia, they include the effect of accompanying obesity and anti-diabetic therapy. One of the anti-diabetic drugs that reduces frequency and improves prognosis of breast carcinoma is metformin. Anticancer effects of metformin are indirect (insulin dependent) and direct (insulin independent). Insulin-dependent and insulin-independent antitumor effect of metformin opens the door for implementation of this drug in therapy and prevention of breast cancer and other malignant diseases even in patients without type 2 diabetes. This paper presents literature data on mechanisms of type 2 diabetes impact to the risk of development and prognosis of breast cancer and the anticancer potential of metformin.\",\"PeriodicalId\":35645,\"journal\":{\"name\":\"Archive of Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2298/AOO1204062P\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archive of Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2298/AOO1204062P\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archive of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2298/AOO1204062P","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 3

摘要

2型糖尿病和恶性疾病是全世界最常见的发病和死亡原因。大量研究表明，糖尿病患者乳腺癌和其他癌症发病率更高，预后更差。2型糖尿病对乳腺癌发生频率和预后的影响机制复杂，除了胰岛素抵抗、高胰岛素血症和高血糖的直接影响外，还包括伴随肥胖和抗糖尿病治疗的影响。二甲双胍是降低乳腺癌发病率、改善乳腺癌预后的降糖药物之一。二甲双胍的抗癌作用是间接的(胰岛素依赖)和直接的(胰岛素独立)。二甲双胍的胰岛素依赖型和胰岛素非依赖型抗肿瘤作用为该药在治疗和预防乳腺癌及其他恶性疾病甚至非2型糖尿病患者中的应用打开了大门。本文就2型糖尿病对乳腺癌发生风险和预后的影响机制以及二甲双胍的抗癌潜力等方面的文献资料进行综述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Influence of metformin therapy on breast cancer incidence and prognosis

Diabetes mellitus type 2 and malignant diseases are among the most frequent causes of morbidity and mortality worldwide. Number of studies showed that breast carcinoma and other cancers are more frequent and have worse prognosis in patients with diabetes. The mechanisms of effect of type 2 diabetes to frequency and prognosis of breast carcinoma are complex and besides a direct effect of insulin resistance, hyperinsulinemia and hyperglycemia, they include the effect of accompanying obesity and anti-diabetic therapy. One of the anti-diabetic drugs that reduces frequency and improves prognosis of breast carcinoma is metformin. Anticancer effects of metformin are indirect (insulin dependent) and direct (insulin independent). Insulin-dependent and insulin-independent antitumor effect of metformin opens the door for implementation of this drug in therapy and prevention of breast cancer and other malignant diseases even in patients without type 2 diabetes. This paper presents literature data on mechanisms of type 2 diabetes impact to the risk of development and prognosis of breast cancer and the anticancer potential of metformin.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Archive of Oncology Medicine-Oncology

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

12 weeks

期刊介绍： Archive of Oncology is an international oncology journal that publishes original research, editorials, review articles, case (clinical) reports, and news from oncology (medical, surgical, radiation), experimental oncology, cancer epidemiology, and prevention. Letters are also welcomed. Archive of Oncology is covered by Biomedicina Vojvodina, Biomedicina Serbica, Biomedicina Oncologica, EMBASE/Excerpta Medica, ExtraMED and SCOPUS.